About

Aditi Puri Singh, MD, is an Assistant Professor of Clinical Medicine in Hematology-Oncology at the University of Pennsylvania's Perelman School of Medicine. She serves as Vice Chair of the Abramson Cancer Center/Cancer Service Line, Associate Chief Oncology Informatics Officer at the Abramson Cancer Center, and Director of Clinical Informatics for the Division of Hematology/Oncology. Her clinical expertise includes lung neuroendocrine tumors (NETs), lung cancers, head and neck cancers, and thymic cancers. Dr. Singh's work also encompasses informatics and electronic health records, contributing to the integration of clinical data and healthcare technology. Her research and publications focus on lung cancer management, genomic profiling, circulating tumor DNA, and personalized treatment approaches, with a particular emphasis on improving patient outcomes through innovative clinical and informatics strategies.

Research topics

• Oncology
• Medicine
• Internal medicine
• Intensive care medicine
• Family medicine

Selected publications

• Renal cell carcinoma masquerading as acute exacerbation of right-sided heart failure: a case report

  Journal of Medical Case Reports · 2026-01-21

  articleOpen accessSenior author

  BACKGROUND: Renal cell carcinoma is the most common malignancy involving the kidney. This cancer has a propensity for extensive invasion and metastatic spread. Tumor thrombus invasion into the inferior vena cava or renal vein occurs in less than 15% of patients with late stage renal cell carcinoma. Further extension up the inferior vena cava into the chambers of the heart is exceedingly rare, documented in less than 1% of all cases. CASE PRESENTATION: Here, we report a case of renal cell carcinoma presenting with what appeared to be an acute exacerbation of right-sided congestive heart failure and fluid overload in a 59-year-old African American male patient. Subsequent imaging revealed the presence of a primary renal cell carcinoma, diffuse metastatic lesions, and intravascular tumor thrombus extension from the inferior vena cava into the right atrium. CONCLUSION: This case highlights the diagnostic challenges of RCC due to its diverse metastatic potential and propensity for multisystem complications. Furthermore, it emphasizes the importance of considering a broad range of possibilities in the clinical context of suspected occult malignancy.

  PublisherDOI

• Safety and Efficacy of Sequential Chemoimmunotherapy Followed by Concurrent Chemoradiation in Unresectable Stage III NSCLC

  JTO Clinical and Research Reports · 2025-08-22

  articleOpen access

  Background: The eighth edition of the International Association for the Study of Lung Cancer staging project reports a 5-year overall survival (OS) for stage IIIA, B, and C NSCLC of 41%, 24%, and 12%, respectively, highlighting the need for improved treatment options. Induction chemotherapy and immune checkpoint inhibition (ID-chemo-ICI) followed by concurrent chemoradiation (cCRT) has not been adequately studied because of concerns about toxicity. We aim to describe the outcomes of patients with unresectable stage III NSCLC who received ID-chemo-ICI followed by cCRT with or without maintenance ICI. Methods: We conducted a retrospective analysis of patients with unresectable stage III NSCLC who received ID-chemo-ICI with the intent to proceed with cCRT across all Mayo Clinic sites. Clinical end points included progression-free survival (PFS), OS, overall response rate per the Response Evaluation Criteria in Solid Tumors version 1.1, and treatment-related adverse events defined using Common Terminology Criteria for Adverse Events version 5.0. Results: A total of 29 patients with unresectable stage III NSCLC, deemed unsuitable for upfront cCRT or surgery, with a plan to proceed with ID-chemo-ICI before cCRT, were identified. The median age was 66 years, 55% were male, most had a history of smoking (93.1%), and 100% identified as White. Tumor histologies were adenocarcinoma (69%), squamous cell carcinoma (24%), poorly differentiated NSCLC (3.4%), and sarcomatoid NSCLC (3.4%). Most were stage IIIB (44.8%), followed by IIIC (41.4%), and IIIA (13.8%). N2 and N3 disease were present in 37.9% and 55.2%, respectively. Programmed death-ligand 1 expression included less than 1% (n = 11, 38%), 1% to 49% (n = 9, 31%), greater than 50% (n = 5, 17%), and unknown (n = 4, 14%). Patients received ID-chemo-ICI with pembrolizumab (82.8%), nivolumab (13.8%), or atezolizumab (3.4%), with a median of four cycles. The overall response rate to ID-chemo-ICI was 93%. Of the cohort, 90% received cCRT, and 76% received maintenance ICI (pembrolizumab or durvalumab). The median PFS was 18 months, and the median OS was 24 months. Pneumonitis occurred in 37.9% (grade 1: 18.2%; grade 2: 63.6%; grade 3: 18%, no grade 4). Esophagitis occurred in 55.2% (grade 1-2: 93%; grade 3: 7%). Conclusions: ID-chemo-ICI followed by cCRT seems feasible and safe for unresectable stage III NSCLC, particularly for patients unsuitable for upfront cCRT. Larger prospective trials are needed to validate these findings and optimize patient selection.

  PublisherDOI

• Contributors

  Elsevier eBooks · 2025-01-01

  book-chapterOpen access
  PublisherDOI

• Comparative Analysis of Healthcare-Associated Infections in Gastroenterology and Gastro surgery: A Two-Year Retrospective Study at GB Pant Hospital, New Delhi

  Journal of Medical Bacteriology · 2025-05-10

  articleOpen access

  Background: Healthcare-associated infections (HAIs) pose significant challenges in gastroenterology and gastrosurgery. This study aimed to compare infection characteristics between these two patient populations at a tertiary care center in India, focusing on gastro-specific samples. Methods: We conducted a retrospective observational study of 824 patients (412 each in gastroenterology and gastrosurgery) over 24 months at GB Pant Hospital, New Delhi. Infections were defined using CDC criteria. Microbiological identification and antimicrobial susceptibility testing were performed on gastro-specific samples. Risk factors were analyzed using multivariate logistic regression. Results: Infection rates were significantly higher in gastrosurgery patients (18.4% vs. 7.5%, p<0.001). Escherichia coli was the predominant pathogen in both groups (gastroenterology: 30.6%, gastrosurgery: 28.9%). Antimicrobial resistance was more prevalent in gastrosurgery isolates, with 48.7% ESBL- producing Enterobacteriaceae compared to 27.3% in gastroenterology. Independent risk factors for infection differed between groups, with proton pump inhibitor use significant in gastroenterology (OR 2.3, 95% CI 1.5-3.5) and prolonged operative time in gastrosurgery (OR 2.8, 95% CI 1.9-4.2). Conclusion: Significant differences in infection profiles between gastroenterology and gastrosurgery patients necessitate tailored prevention and treatment strategies.

  PublisherDOI

• Immune Checkpoint Inhibitors for Patients With Preexisting Autoimmune Neurologic Disorders

  JAMA Network Open · 2025-06-04 · 12 citations

  articleOpen access

  Importance: Immune checkpoint inhibitors (ICIs) are efficacious in many cancer types but can produce immune-related adverse events (irAEs). As such, patients with preexisting autoimmune disorders are often excluded from clinical trials, although subsequent studies have shown that many of these patients have acceptable ICI tolerance. The safety and efficacy of ICIs among patients with preexisting neurologic autoimmune disorders (NAIDs) is not well characterized. Objective: To evaluate the safety and clinical outcomes associated with ICI therapy among patients with NAIDs. Design, Setting, and Participants: This multicenter retrospective cohort study included patients with cancer who were treated with ICIs between October 2013 and May 2023 and had preexisting multiple sclerosis (MS), myasthenia gravis (MG), Guillain-Barré syndrome (GBS), and other NAIDs as well as a control cohort of patients with Parkinson disease (PD). Exposure: ICI therapy. Main Outcomes and Measures: Demographic and clinical characteristics (neurologic disability, active or recent immunosuppression), ICI outcomes (response, progression-free survival [PFS], and overall survival [OS]), and safety outcomes (NAID exacerbation, irAEs) were collected. Results: A total of 135 patients were included; the median (range) age was 72 (40-88) years, 84 (62%) were men, and 51 (38%) were women. A total of 45 patients had MS; 18, MG; 10, GBS; 5, another NAID; and 57, PD. Exacerbations occurred most frequently in MG (12 of 18 patients [67%]), often resulting in hospitalization (6 [50%]) or death (2 [17%]), with much lower rates in the MS cohort (8 of 45 patients [18%]). Ten patients with a history of GBS tolerated ICI without exacerbations, although 1 developed a fatal case of Lambert Eaton myasthenic syndrome following ICI treatment. No differences in response rate, PFS, or OS were observed between NAID groups. Conclusions and Relevance: In this cohort study of ICI use in NAIDs, patients with MG had frequent and more severe exacerbations, while those with MS had few exacerbations. No obvious differences in survival between groups were observed. ICI may be an option for many patients with appropriate oncologic indications and preexisting NAIDs.

  PublisherOA PDFDOI

• Optimizing the Electronic Health Record for Patient-Centered Cancer Care

  2025-02-17

  dataset

  Dr. Chino talks with Dr. Aditi Singh and patient advocate Liz Salmi about how this essential tool for documentation could be optimized to be more patient-centered. This discussion will be based off the JCO OP article published in late 2024, “Re-Envisioning the Electronic Health Records to Optimize Patient-Centered Cancer Care, Quality, Surveillance, and Research,” on which Dr. Singh served as the lead author.

  PublisherDOI

• Generation of Pull Request Description using Transformers

  Research Square · 2025-08-05

  preprintOpen access
  PublisherOA PDFDOI

• Prognostic Implications of Detectable Postoperative Tumor Tissue-Modified HPV DNA in Patients with p16+ Oropharyngeal Squamous Cell Carcinoma Undergoing De-Intensified Adjuvant Radiation

  International Journal of Radiation Oncology*Biology*Physics · 2025-09-01

  article
  PublisherDOI

• Thymomas and Thymic Carcinomas, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology

  Journal of the National Comprehensive Cancer Network · 2025-06-01 · 18 citations

  article

  Thymomas and thymic carcinomas are rare mediastinal tumors that originate in the thymus. Patients with thymoma may experience symptoms associated with autoimmune paraneoplastic diseases (such as myasthenia gravis), which typically do not occur in patients with thymic carcinoma. The NCCN Guidelines for Thymomas and Thymic Carcinomas provide guidance for the diagnosis, treatment, and surveillance of patients with thymoma and thymic carcinoma. Involvement of a multidisciplinary team with experience treating thymomas and thymic carcinomas is highly recommended.

  PublisherDOI

• NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 7.2025

  Journal of the National Comprehensive Cancer Network · 2025-09-01 · 39 citations

  article

  The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) provide recommendations for the treatment of NSCLC. These NCCN Guidelines Insights discuss recent updates to the NCCN Guidelines, with a focus on systemic therapy options for the treatment of patients with nonmetastatic NSCLC and the corresponding molecular testing considerations.

  PublisherDOI

Frequent coauthors

• Corey J. Langer

  University of Pennsylvania

  69 shared

• Roger B. Cohen

  University of Pennsylvania

  68 shared

• Charu Aggarwal

  University of Pennsylvania

  51 shared

• Melina E. Marmarelis

  University of Pennsylvania

  50 shared

• Lova Sun

  University of Pennsylvania

  40 shared

• Christine Ciunci

  University of Pennsylvania

  38 shared

• Joshua Bauml

  31 shared

• Abigail T. Berman

  30 shared

Education

• M.D.

  Lady Hardinge Medical College

  2010